Trials / Completed
CompletedNCT00394446
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Myrexis Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MPC-6827 | 2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2007-04-01
- Completion
- 2008-02-01
- First posted
- 2006-11-01
- Last updated
- 2008-02-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00394446. Inclusion in this directory is not an endorsement.